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sis uses a cohort Markov model to estimate lifetime costs and
QALYs to extrapolate observed clinical trial results (the BIG 
1-98 trial). The model was designed to describe all the relevant
states during the disease course and to capture the incidence 
and costs of all the relevant adverse events the letrozole and
tamoxifen patient groups: endometrial cancer; bone fractures;
myocardial infarction; venous thromboembolic events; and
hypercholesterolaemia. Cost items were obtained from ofﬁcial
data sources and were attached to estimate the resource use by
patients spending a year in each of the health states included in
the model, as well as to resources used to treat the mentioned
AEs. The utility parameters associated with the model’s breast
cancer states are based on a primary utility study, that used the
standard gamble approach to estimate utility values for breast-
cancer related health states. RESULTS: Letrozole treatment for
breast cancer in the early adjuvant setting resulted an additional
388 (discounted) years of disease free survival are gained, with
250 life years, and 277 quality adjusted life years (QALYs). The
incremental cost per life year was HUF 6,060,371, and the incre-
mental cost per QALY was HUF 5,462,685. The lower cost per
QALY than cost per life year gained indicates that the difference
in the utility gained as result of fewer patients experiencing a
distant recurrence outweighs the gain in life years due to the sur-
vival impact of distant recurrence. CONCLUSION: Our cost
utility analyses showed that letrozole was cost-effective as a
treatment for postmenopausal oestrogen receptor positive
women following diagnosis with early breast cancer in Hungary.
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OBJECTIVE: To compare cost and effectiveness of various
schemes of treatment patients with advanced Hodgkin’s disease
and to determine more cost-effective schemes in Russia.
METHODS: In order to determine quantity of drugs and cost of
different treatment schemes we used data from individual
medical documentation (history of disease) in Hematological
Scientiﬁc Center and data from price-lists of pharmaceutical dis-
tributors in Moscow. In order to determine effectiveness we ana-
lyzed data from clinical trials. We chose data from clinical trials,
which is possible to compare. It was data from clinical trial,
which guided German Hodgkin Study Group (GHSG). In this
trial scientists estimated 3 years Freedom from Treatment Failure
(FFTF) of 4 schemes: COPP/ABVD, BEACOPP-baseline,
BEACOPP-escalated and BEACOPP-14. In the end, we calcu-
lated and analyzed cost-effectiveness rates (CER) of different
schemes. RESULTS: Effectiveness of investigating schemes (3
year FFTF) was 70% for COPP/ABVD, 79% for BEACOPP-
baseline, 89% for BEACOPP-escalated and 90% for BEACOPP-
14. Cost of treatment by these schemes was 138,600 rubles
(€3960), 125,500 rubles (€3586), 537,900 rubles (€15,370), and
503,900 rubles (€14,400) (35 rubles = 1 Euro) for COPP/ABVD,
BEACOPP-baseline, BEACOPP-escalated and BEACOPP-14,
respectively. CER for these schemes was 1979, 1588, 6043, and
5598 rubles per percent or 57, 45, 173, and 160 euros per
percent, for COPP/ABVD, BEACOPP-baseline, BEACOPP-esca-
lated and BEACOPP-14, respectively. BEACOPP-baseline had
minimal CER but BEACOPP-escalated and BEACOPP-14 were
more effective and more expensive. BEACOPP-14 was less
expensive and more effective than BEACOPP-escalated. Thus,
BEACOPP-baseline and BEACOPP-14 are more cost-effective
than COPP/ABVD and BEACOPP-escalated, respectively. CON-
CLUSIONS: We compared cost and effectiveness of 4 therapy
schemes of advanced Hodgkin’s disease and determined more
cost-effective schemes (BEACOPP-baseline and BEACOPP-14).
In order to choose between BEACOPP-baseline and BEACOPP-
14 we have to know budget, which payer has, or price, which
payer is able to pay for treatment.
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OBJECTIVE: OM is a frequent, serious, and one of the most
debilitating side effect among patients who undergo myelosup-
pressive therapy and hematologic stem cell transplants. Palifer-
min is the ﬁrst and only mucosal growth factor indicated to
decrease the incidence, duration and severity of OM in patients
with haematological malignancies receiving myeloablative
therapy associated with a high incidence of severe mucositis and
requiring ASCT. Assess palifermin CE in the prevention of OM
in patients requiring ASCT in Spain. METHODS: CE was
assessed based on a palifermin phase 3 clinical trial (1) compar-
ing palifermin with best supportive care (BSC), local mean hos-
pital costs (1051,50€ per-diem) (2) and assuming palifermin
ex-manufacturer price of 4.700€/treatment. A sensitivity analy-
sis applying a correction factor of 15% to hospital cost since
severity of OM is associated with an increase utilization of health
care resources. (3) Effectiveness measured in terms of number
days reduction with OM and decrease of grades 3/4 OM inci-
dence. RESULTS: Compared to BSC, palifermin effectively
decreased the duration of severe (WHO grade 3 or 4) OM from
9 to 3 days (p < 0.001) (1), and was associated with a lower inci-
dence of severe OM (98% vs 63%; p < 0.001) (1), and reduced
post-transplant inpatient stay by 1.9 days (from 17,2 to 15,3; p
= 0,008) (4). The CE model shows an incremental cost-effec-
tiveness ratio (ICER) of using palifermin over BSC of 7.720,43€
per episode of grade 3/4 OM avoided and an ICER of 450,36€
per day of grade 3/4 OM avoided. Adjusting for severity of OM,
the ICER are €825,60 per episode of grade 3/4 OM avoided and
€48,16 per day of grade 3/4 OM avoided. CONCLUSIONS: Pal-
ifermin is a cost-effective therapy for ASCT patients. When
taking into account the impact of OM severity OM on health
care resources, palifermin could be a cost-neutral intervention.
[1] Spielberger R, et al. N Engll 2004 Dec 16;351:2590–8 2
Spain MOH (MSC 2002) 3 Sonis, et al. Journal Clinical Oncol-
ogy. 2001;19:2201–2205 4 Emmanouilides C, et al. Blood
2003;102(11): Abstract #883.
PCN23
ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY IS
COST NEUTRAL AND CLINICALLY SUPERIOR IN ADVANCED
STAGE NON-HODGKIN’S LYMPHOMA (NHL)
Hieke K1, Herold M2
1NEOS Health, Binningen, Switzerland, 2HELIOS Klinikum Erfurt,
Erfurt, Germany
OBJECTIVES: To identify cost and cost effectiveness of R-MCP
(rituximab, mitoxantrone, chlorambucil, prednisolone) vs. MCP
in NHL-patients from the perspective of a third party payer in
Germany (statutory sickness fund). METHODS: Resource uti-
lization data on 329 patients were collected in parallel to a RCT
